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Patientswith hyperventilation syndrome (HVS) report severe symptom-related suffering and often
complain from insufficient medical attention. However, quality of life data in this context are
scarce. We aimed at assessing the health-related quality of life (HRQoL) of HVS patients.
Twenty-one HVS patients with extensive cardiorespiratory workup including cardiopulmonary ex-
ercise testing (CPET) filled in the generic SF-36 questionnaire and the results were compared to
Frenchnormal values. Correlations between SF36dimensions and clinical and functional datawere
established. All SF-36 scores were markedly decreased in HVS patients compared to healthy sub-
jects: Physical Functioning: 44  24, Social Functioning: 57  27, Role Physical: 21  32, Role
Emotional: 48 42, Mental Health: 51 27, Vitality: 34 20, Body Pain: 41 21, General Health:
42  21. These figures were all significantly lower in the HVS patients respective to the normal
reference population. They were also lower than corresponding values published in patients with
asthma or chronic obstructive pulmonary disease (COPD). “Vitality” and “Physical Functioning”
scores were correlated with Nijmegen score (rZ 0.594, pZ 0.047) and peak respiratory fre-
quency during CPET (rZ 0.644, pZ 0.019). The SF-36 Social Functioning score was correlatedneumologie et Re´animation Me´dicale, Groupe Hospitalier Pitie´-Salpeˆtrie`re Charles Foix, 47-83 Bd de
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518 C. Chenivesse et al.with the ventilatory threshold (rZ 0.629, pZ 0.034), peak V0E/V0CO2 (ventilation/CO2 produc-
tion) (rZ 0.650, pZ 0.016) and peak PaCO2 (rZ 0.664, pZ 0.027).
In conclusion, this study shows that HRQoL can be severely impaired in patients with HVS, which
is one more reason to take this condition seriously.
ª 2013 Elsevier Ltd. All rights reserved.Background
The term “hyperventilation syndrome” (HVS) designates a
condition comprising a variety of somatic and psychological
symptoms associated with physiologically inappropriate
alveolar hyperventilation [1,2] that may be chronic or trig-
gered by mental stress or exercise. The symptoms (primarily
dyspnea, but also chest pain, anxiety or even panic attacks [3]
and many other manifestations) are episodic in nature. No
clear pathophysiological mechanism has been identified. HVS
is difficult to diagnose because of the labile nature of the
symptoms, the absence of any readily identifiable somatic
abnormality, and the absence of a gold standard diagnostic
method. HVS may be isolated, in the presence of normal
cardiorespiratory function (“idiopathic HVS”), but can also
occur inpatientswithother respiratorydiseases (for example,
asthma), which further complicates the diagnostic. In these
settings, the diagnosis of HVS can be considered when the
documented abnormalities are insufficient to explain the
symptoms or blood gas abnormalities. Several diagnostic tools
have been proposed, including the Nijmegen questionnaire
[4], reproduction of symptoms during voluntary hyperventi-
lation challenge [5e8], measurement of gas exchanges during
exercise [9] or during a shift from the sitting to the standing
position [10]. However, none of these diagnostic tools are
completely satisfactory.Ofnote, arterial hypocapniaat rest is
a useful clue to HVS, but is probably the hallmark of more
chronic and/or more severe forms of the condition.
For the above reasons (diversity and lability of symptoms,
their intricate association with anxiety, lack of clear patho-
physiology, diagnostic difficulties), HVS tends to be poorly
perceived and often neglected by both general practitioners
and specialists. However, clinical experience suggests thatHVS
patients may suffer severely from their condition. Exercise
intolerance [11] and an exaggerated feeling of the unpleas-
antness of dyspnea for a given level of perceptual intensity are
probably important causes of this suffering [12]. HVS patients
report that the limited attention paid by doctors to their con-
dition also contributes to their distress. The impact of HVS on
health-related quality of life (HRQoL) has however not been
extensively described.Wehypothesized that HVSwould have a
major negative impact onHRQoL, and tested this hypothesis by
applying the French version of the generic SF-36 questionnaire
[13] in a population of patients diagnosed with HVS.Methods
Setting
The study was conducted in a tertiary referral dyspnea clinic
run by the 86-bed respiratory medicine unit of a teachinghospital. All patients referred to this clinic are systemati-
cally assessed by pulmonary function tests (PFTs), room air
arterial blood gases and Doppler echocardiography when not
already available in their charts. Cardiopulmonary exercise
testing (CPET) is also performed for the purposes of differ-
ential diagnosis and to evaluate the disproportionateness of
dyspnea in cases of HVS associated with respiratory abnor-
malities. When HVS is suspected on the basis of these ex-
aminations, the Nijmegen questionnaire (16 items related to
common complaints due to chronic hyperventilation) is also
applied and a hyperventilation provocation test (HVPT) is
performed (see below,Methods). The French Sadoul dyspnea
scale [14] and the Baseline Dyspnea Index [15] are system-
atically measured. The present study was approved by the
French learned society institutional review board (“Socie´te´
de Pneumologie de Langue Franc¸aise” reference number
CEPRO2012-009) and patients gave their consent to anony-
mous use of their data for research purposes.Inclusion criteria
Patients were included in the study when they met the
following criteria:
- at least two compatible clinical symptoms among dys-
pnea, chest tightness, chest pain, palpitations, blurred
vision, dizzy spells, bloated feelings in stomach,
tingling fingers, stiff fingers or arms, feeling of tightness
around the mouth, cold hands or feet, feeling tense or
feelings of anxiety;
- resting hypocapnia with PaCO2 <38 mmHg with a
normal alveolar-arterial gradient for oxygen (PA-aO2);
- absence of significant obstructive or restrictive venti-
latory defects on PFTs;
- absence of pulmonary artery hypertension on Doppler
echocardiography;
- absence of exercise-induced increase of PA-aO2.
- at least two criteria among: Nijmegen score 23 [4];
reproduction of at least 2 usual symptoms during HVPT
and delayed return of the end-tidal partial pressure of
carbon dioxide in the expired gas (PETCO2) to baseline
during HVPT (see below).Pulmonary function testing
Spirometry, plethysmography and single-breath lung
diffusing capacity for carbon monoxide (DLCO) were per-
formed in all patients (Jaeger Masterscreens Body) ac-
cording to the joint guidelines of the American Thoracic
Society and of the European Respiratory Society [16e18].
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values [16e18].
Cardiopulmonary exercise testing
All patients underwent a maximal, symptom-limited, in-
cremental and triangular exercise test on an Ergoline-
Ergometrics 800 ergometric bicycle. The protocol con-
sisted of a 3-min warm-up period (20 Watts) followed by
progressively increasing work rate of 10 W/min until
maximal tolerance, and then a 2-min recovery period.
Heart rate, blood pressure, 12-lead electrocardiogram and
oxyhemoglobin saturation were monitored continuously.
The content of expired gases was determined on a breath-
by-breath basis (Ergocard, Medisoft, Sorinnes, Belgium) to
monitor oxygen consumption (V0O2), carbon dioxide pro-
duction (V0CO2), minute ventilation (V0E) and tidal volume
(VT). Blood samples were taken from the radial artery at
rest and at peak exercise to measure blood gases and lactic
acid. Forced expiratory flowevolume curves were recorded
at the end of exercise. The alveolar-arterial gradient in
oxygen (PA-aO2) was calculated from the alveolar gas
equation [19]. The ventilatory “anaerobic” threshold (VThr)
was determined by using both the “Equivalents” method
and the “V0 slope” method [19]. Ventilatory reserve (VR)
was calculated as recommended [19]. The dead space-to-
tidal volume ratio (VD/VT) was calculated according to
Bohr’s equation corrected for the additional instrumental
dead space [19]. The results were expressed as percentage
of predicted values [19].
Hyperventilation provocation test
HVPTs were performed as previously described [6,7].
Briefly, patients were required to breathe through a large
pneumotachograph (Hans Rudolph 2700 series, Hans
Rudolph, Kansas City, MO, USA) and PETCO2 was continu-
ously monitored using a mainstream capnograph (Datex-
Ohmeda, Limonest, France). A 3-min baseline recording
period was followed by a 3-min voluntary hyperventilation
period designed to decrease baseline PETCO2 by 50%. Pa-
tients were then instructed to breathe normally for
10 min or until return of PETCO2 to baseline, whichever
occurred first. At the end of the test, the patients were
asked to describe the symptoms experienced during the
test. PETCO2 recovery lasting more than 5 min was
considered to be abnormal [6,7].
Health-related quality of life (HRQoL)
HRQoL was assessed by the validated French version of the
Short Form 36 questionnaire (SF-36) [13]. This question-
naire comprises 36 questions organized into eight multi-
item scales: physical functioning (PF), social functioning
(SF), role limitations as a result of physical problems (RP),
role limitations as a result of emotional problems (RE),
mental health (MH), vitality (frequency of feeling full of
energy vs. feeling tired, VT), body pain (BP) and general
health perception (GH). A 0-100 score is allocated, where
100 indicates optimal conditions.Statistical analysis
Statistical analyses were performed with SPSS software
(SPSS for Mac OS, version 11.0.2, 2006. Chicago: SPSS Inc,
US). Results related to general characteristics and pulmo-
nary function tests are expressed as median, first quartile
(Q1) and third quartile (Q3). Results for SF-36 scores are
expressed as mean and standard deviation, as all SF36 re-
sults were normally distributed (KolmogoroveSmirnov
test). Differences between means are expressed as mean
and 95% confidence interval. Cronbach’s a coefficients
analysis was used to determine the internal consistency of
each SF-36 item. Coefficients were considered robust when
Cronbach’s a values exceeded 0.7 [20]. Z-scores and 95%
confidence intervals (95% CI) of the difference between
means were used to describe differences in SF36 scores
between HVS patients and a healthy French population
[21]. Z-scores were compared to zero with a Wilcoxon
signed-rank test, with p Z 0.05 as the limit of statistical
significance. Multiplicity was accounted for by using the
Benjamini and Hochberg multiple testing correction [22]. A
mean Z-score <0.6 was considered to be not clinically
significant. Clinical significance was considered minor for
1.3 < Z < 0.6, moderate for 2 < Z < 1.3, and major
for Z < 2.
Results
Patient characteristics and pulmonary function
tests
Twenty-one patients satisfied the inclusion criteria (Table
1). Ten of these patients were both non-smokers and
completely free of any past or present respiratory disor-
ders, while the other 11 patients did not meet these two
criteria, but reported dyspnea with an intensity considered
to be disproportionate to their respiratory status (3 smokers
with normal spirometry; 3 asthmatics with stable and well
controlled asthma according to the 5-item Asthma Control
Questionnaire (ACQ-5 < 1,5); 2 patients with a distant
history of pulmonary embolism; 3 patients with a distant
history of stage I sarcoidosis; 1 patient with pleural pla-
ques). Fig. 1 summarizes the dyspnea scores.
Diagnosis of HVS
The diagnosis of HVS was adopted on the basis of a com-
bination of a Nijmegen score 23 and reproduction of the
usual symptoms by HVPT in 2 cases, a Nijmegen score 23
and delayed PETCO2 recovery in 2 cases, reproduction of
the usual symptoms during HVPT and delayed PETCO2 re-
covery in 4 cases; all three criteria were present in 13
cases. Of note, the estimated interval between the first
HVS-related complaints and diagnosis exceeded 2 years in
50% of cases.
Cardiopulmonary exercise testing
All CPETs were maximal and symptom-limited and consis-
tently demonstrated normal cardiac, pulmonary and
Table 1 Characteristics of HVS patients (n Z 21) and
pulmonary function test results.
M (Q1eQ3)
General characteristics
Age (years) 47 (36e54)
Sex ratio M/F 5/16
BMI (kg m2) 24 (20e28)
Smoker/Ex-smoker/Never smoker 6/5/10
Pulmonary function testing
FEV1 (% pred) 103 (95e115)
FEV1/FVC (%) 80 (78e85)
TLC (% pred) 106 (96e114)
DLCO/VA (% pred) 91 (81e106)
Resting arterial blood gases
pH 7.45 (7,44e7.48)
PaO2 (mmHg) 99.2 (92e104.7)
PaCO2 (mmHg) 32.3 (29.3e34.9)
FEV1: forced expiratory volume in one second; FVC: forced vital
capacity; TLC: total lung capacity; DLCO: diffusing capacity of
the lungs for carbon monoxide, VA: alveolar volume.
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HVS. Aerobic capacity was reduced (namely below 84%
pred) in 15/21 patients [19]. All but 2 of the HVS patients
presented marked hyperventilation during exercise with
elevated ventilatory equivalents (V0E/V0CO2 Z 38, median
V0E/V0O2 Z 40, predicted values <34) [19]. The detailed
CPET results are provided in Appendix 1.
Health-related quality of life
The SF-36 internal consistency was satisfactory for the
whole questionnaire and for each subscale, as confirmed by
high Cronbach’s a coefficients [0.7e0.9]. SF-36 results are
summarized in Table 2 and Fig. 2. HVS patients displayed
significant impairment in all HRQoL domains, including
physical (particularly role physical), mental and social di-
mensions, with a dramatic reduction of the physical com-
ponents PF and RP.Figure 1 Dyspnea score histograms (Sadoul scale, A; baseline d
intense exercise) to 5 (dyspnea for activities of daily living). The Ba
(absence of dyspnea).Cross-correlations
Spearman’s correlations coefficients were calculated be-
tween SF36 dimensions, dyspnea scores, Nijmegen score,
resting ventilation and PETCO2, and the various variables
measured during CPET. Five of these tests resisted the
Benjamini and Hochberg correction for multiple compari-
sons [22]. The SF-36 “vitality” score (VT) was significantly
negatively correlated with the Nijmegen score, as a higher
Nijmegen score was associated with a lower VT score
(r Z 0.594, pZ 0.047). The SF-36 “physical functioning”
(PF) score was significantly negatively correlated with peak
respiratory frequency during exercise, as higher peak res-
piratory frequency was associated with lower PF score
(r Z 0.644, p Z 0.019). The SF-36 “social functioning
score” was significantly correlated with the ventilatory
threshold ATV0E (rZ 0.629, pZ 0.034) and peak V0E/V0 CO2
(r Z 0.650, p Z 0.016), and negatively correlated with
PaCO2 at peak exercise (r Z 0.664, p Z 0.027).
Discussion
The results of this study show that SF-36 domain scores can
be extremely low in patients with hyperventilation
syndrome.
Severity
To our knowledge, this is the first time that health-related
quality of life has been specifically documented in a group
of patients meeting strict criteria for HVS, namely a com-
bination of symptoms and resting hypocapnia. However,
Hagman et al. [23] reported low SF-36 subscores in 25 pa-
tients with “dysfunctional breathing”, a term that de-
scribes patients presenting the HVS constellation of
symptoms, but with or without breathing pattern abnor-
malities and with or without resting hyperventilation. In
this study, “dysfunctional breathing” patients had signifi-
cantly lower SF-36 scores than asthmatic controls. SF-36
subscores were as follows: physical functioning 78, social
functioning 70, role limitationsdphysical 60, role limi-
tationsdemotional 64, mental health 71, vitality 47, bodilyyspnea index, B). The Sadoul scale ranges from 1 (dyspnea at
seline Dyspnea Index (BDI) ranges from 0 (resting dyspnea) to 12
Table 2 Health-related quality of life in HVS patients: SF-36 raw scores and Z-scores, and difference of mean SF36 scores





p Difference between means
Mean (95% CI)
PF 44  24 2.5  1.5 <0.001 43 (53 to 31)
RP 21  32 2.2  1.0 0.007 64 (78 to 49)
BP 41  21 1.4  1.0 <0.001 33 (42 to 23)
GH 42  21 1.6  1.2 <0.001 28 (38 to 18)
VT 34  20 1.4  1.1 <0.001 26 (35 to 17)
SF 57  27 1.2  1.3 <0.001 24 (37 to 12)
RE 48  42 1.1  1.3 0.001 36 (55 to 18)
MH 51  27 0.93  1.5 <0.001 16 (29 to 4)
PF: physical functioning, SF: social functioning, RP: role limitations as a result of physical problems, RE: role limitations as a result of
emotional problems, MH: mental health, VT: vitality, BP: body pain, GH: general health perception.
Figure 2 A. Radar plot showing mean SF-36 scores in HVS pa-
tients included in this study (solid line) and in the general healthy
French population (dotted line). Each spoke on the plot repre-
sents a SF-36 dimension. PF, physical functioning; SF, social
functioning; RP, role limitations as a result of physical problems;
RE, role limitations as a result of emotional problems; MH,mental
health; VT, vitality (the frequency of feeling full of energy vs.
feeling tired); BP, bodypain;GH, general health perception. Plots
are read from the center outward along each spoke. Scores are
shown on concentric circles beginning with 0 (at the center) and
increasing to 100 (outer line). “Healthy” values are derived from
[21]. B. SF-36 Z-scores of patients with HVS (mean with standard
deviation) compared with age- and sex-matched controls in a
French cohort (zero line). A negative Z-score indicates a lower
health status in the HVS group. PF: physical functioning, RP: role
physical, BP: bodily pain, GH: general health, VT: vitality, SF:
social functioning, RE: role emotional, MH: mental health.
HRQoL and chronic hyperventilation 521pain 62, and general health perception 53 [23]. These fig-
ures are much higher than those observed in our patients
(Table 2), who all exhibited resting hypocapnia (PaCO2 less
than 38 mmHg constituted an inclusion criterion, see
Methods). The presence of resting hypocapnia and the fact
that these patients were referred to a tertiary care center
strongly suggest that this population was biased toward
more marked severity, as resting hypocapnia is not always
present in HVS patients and many of them become hypo-
capnic only in response to emotional or physical stimula-
tion. The differences between the values observed in our
patients and normal French subjects are therefore partic-
ularly striking (Table 2). These values are also much lower
than published SF-36 scores for patients with other respi-
ratory diseases such as cystic fibrosis [24], chronic
obstructive pulmonary disease [25] or severe asthma [26]
(Table 3). They are also much lower than the scores
observed in patients with social anxiety disorder and panic
disorder not selected for the hyperventilation criterion
[27].
Functional correlations
In addition to indicating the possible severity of HVS-
related impairment of HRQoL, this study also demon-
strated statistically significant correlations between SF-36
subscores and physiological characteristics. The physical
functioning subscore was negatively correlated with peak
respiratory frequency during exercise, whereas the social
functioning subscore was negatively correlated with PaCO2
at maximal exercise, an indicator of the intensity of hy-
perventilation. These results reinforce our findings and give
further support to the “reality” of the patients’ suffering,
as the intensity of hyperventilation appears to be directly
correlated with the severity of HRQoL impairment. The
correlation between the Nijmegen score and the SF-36 vi-
tality subscore can be considered to support the value of
the Nijmegen questionnaire.
Methodological considerations and limitations
In this study, we chose to use the SF-36 as a generic mea-
sure of HRQoL rather than a more specific respiratory
questionnaire. One reason to choose the SF-36 over a
Table 3 Published SF-36 scores in patients with cystic
fibrosis [24] chronic obstructive pulmonary disease [25],
asthma [26] and HVS (our study) (mean  SD).
HVS Cystic fibrosis Asthma COPD
PF 41  23 76  24 78  20 60  20
SF 54  28 80  24 85  19 83  21
RP 17  29 73  38 75  40 68  33
RE 39  42 77  37 70  35 88  27
MH 49  24 74  18 63  19 79  13
VT 34  18 58  23 57  21 61  14
BP 41  23 83  21 73  27 89  18
GH 42  20 43  24 61  22 49  16
PF: physical functioning, SF: social functioning, RP: role limi-
tations as a result of physical problems, RE: role limitations as a
result of emotional problems, MH: mental health, VT: vitality,
BP: body pain, GH: general health perception, COPD: chronic
obstructive pulmonary disease.
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that patients with the HVS describe an array of symptoms
that go way beyond dyspnea and respiratory abnormalities.
This is well attested to by the very content of the Nijmegen
questionnaire that includes digestive symptoms, neuropsy-
chological manifestations, etc. In addition, generic HRQoL
measures have the advantage of allowing comparison be-
tween clinical groups and healthy populations or between
clinical groups [28]. Our data can therefore be compared to
published data for the general French healthy population
[21,28]. Of note, as SF-36 has not been previously used in
HVS patients, its internal consistency had to be evaluated
in our population [20,29]. Cronbach’s a coefficient values
obtained in this study (>0.7) were reassuring. The small
size of our study population and the likely bias toward
severity (see above) preclude any attempt at generaliza-
tion. The fact that about one half of the patients in this
study were symptomatic smokers or had a past history of
respiratory diseases could also constitute confounding
factors, but these patients did meet the defined HVS
criteria including normal resting cardiopulmonary function
and their breathlessness clearly appeared to be dispropor-
tionate. Finally, our study is subject to the same limitations
as other HVS studies, namely the lack of a formal positive
diagnostic test. The Nijmegen score has high sensitivity but
lacks specificity [4] and the hyperventilation provocation
test can give false-positive results [4,8]. However, as stated
above, our diagnostic criteria for HVS were more stringent
than those used in most studies.M (Q1eQ3)
Peak V0O2 (% pred) 79 (68e86)
V0E/V0CO2, at VThr 38 (34e48)
V0E/V0O2, at VThr 40 (34e48)
Peak P(Aea)O2 (mmHg) 19 (15e23)
Peak PaO2 (mmHg) 103 (94e109)
Peak VD/VT 0.25 (0.22e0.31)
V0O2: oxygen consumption, V0E: minute ventilation, V0CO2:
carbon dioxide production, VThr: ventilatory threshold, (PA-
aO2): alveolar-arterial PO2 pressure difference, PaO2: oxygen
alveolar pressure, VD/VT: dead space-to-tidal volume ratio.Conclusions
Despite its limitations, this study highlights the putatively
very strong impact of HVS on health-related quality of life.
These results cannot be considered definitive, and it would
be important to extend their scope to a primary care pop-
ulation. However, they provide sufficient incentive for
larger and more detailed studies and support the use of
HRQoL as an outcome measure of therapeutic intervention
studies of HVS. For example, breathing retraining tech-
niques are recommended in HVS patients with or withoutcoexisting asthma [30], but their impact on HRQoL has yet
to be determined. In any case, the findings of this study are
a reminder that HVS patients suffer from a debilitating
condition and warrant medical attention.
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fee for his work.Appendix 1. Detailed CPET results.
All CPET were maximal and symptom-limited. Aerobic ca-
pacity was reduced (<84% pred [19]) in 15/21 patients. A
premature ventilatory threshold (<40% of predicted peak
VO2 [19]) was observed in 3 patients. All but 2 of the HVS
patients presented marked hyperventilation during exer-
cise as demonstrated by increased ventilatory threshold
(VThr) V0E/V0CO2 and V0E/V0O2 (predicted values < 34 [19]).
Breathing pattern and ventilatory rate increased normally
during exercise (peak RR < 60/min; peak VT/FVC > 40%
[19]) except in two patients who presented with both a
peak RR higher than 60/min and a VT/FVC less than 40%.
Ventilatory reserve was reduced in 10 patients (normal V0E/
MVV > 30% [19]). Expiratory flowevolume curves did not
show any airflow limitation at the end of exercise. Peak
alveolar-arterial PO2 pressure difference (P(A-a)O2) was
normal (normal < 35 mmHg [19]) in all patients and no
hypoxemia was observed during exercise. Peak dead space-
to-tidal volume ratio (VD/VT) was normal (<0.30 [10])
except in 6 patients. In these cases, the increased peak VD/
VT was attributed to changes in breathing pattern with
major hyperventilation, small tidal volume and tachypnea
after exclusion of vascular and hemodynamic diseases.
Cardiovascular adaptation was within normal limits in all
patients.
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